Lilly- Incyte Phase 3 baricitinib in hospitalized COVID-19 patients misses endpoint

 - Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death)

- Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated with baricitinib in addition to standard of care, including corticosteroids and remdesivir

https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients-301264421.html